IMTX Stock Summary and Trading Ideas (Immatics N.V. - | NASDAQ:IMTX)

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Immatics N.V. - trades on the NASDAQ stock market under the symbol IMTX.

As of December 11, 2025, IMTX stock price declined to $10.04 with 584,991 million shares trading.

IMTX has a beta of 1.79, meaning it tends to be more sensitive to market movements. IMTX has a correlation of 0.18 to the broad based SPY ETF.

IMTX has a market cap of $1.35 billion. This is considered a Small Cap stock.

Last quarter Immatics N.V. - reported $6 million in Revenue and -$.49 earnings per share. This fell short of revenue expectation by $-6 million and exceeded earnings estimates by $.01.

In the last 3 years, IMTX traded as high as $13.77 and as low as $3.30.

The top ETF exchange traded funds that IMTX belongs to (by Net Assets): SPDW, SBIO, GWX, CANC, RFLR.

IMTX has outperformed the market in the last year with a return of +33.0%, while the SPY ETF gained +15.5%. In the last 3 month period, IMTX beat the market returning +72.8%, while SPY returned +5.9%. However, in the most recent 2 weeks IMTX has underperformed the stock market by returning -5.4%, while SPY returned +1.4%.

IMTX support price is $9.53 and resistance is $10.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMTX shares will trade within this expected range on the day.